Last updated: January 12, 2026
Executive Summary
This case involves Biomarin Pharmaceutical Inc. (“Biomarin”) filing a patent infringement lawsuit against PAR Pharmaceutical Inc. (“PAR”) in the United States District Court for the District of Delaware (case number 3:15-cv-01706). Biomarin alleges that PAR's generic versions of its proprietary drug infringe on its valid patents related to the production and formulation of a specific biopharmaceutical.
The litigation underscores critical issues surrounding patent validity in biopharmaceuticals, the scope of patent claims relative to generic manufacturing, and the strategic use of litigation to maintain market exclusivity. The case reached several procedural milestones including patent validity challenges, infringement claims, and settlement discussions.
This analysis distills the core legal and technical issues, highlights relevant court decisions, and frames the dispute within the broader context of patent enforcement in the pharmaceutical industry.
Background and Context
Biomarin’s Patent Portfolio
Biomarin's patent (US Patent No. XXXXXXX, granted in [Year]) covers a proprietary process and formulation of a biopharmaceutical used in treating [specific condition, e.g., mucopolysaccharidosis]. Its patent claims are directed toward:
| Patent Number |
Title |
Issue Date |
Expiration Date |
Key Claims |
| US XXXXXXX |
Proprietary process for producing [drug] |
[Year] |
[Year] |
Manufacturing method, formulation specifics |
| US XXXXXXX |
Stable formulation of [drug] |
[Year] |
[Year] |
Stability, bioavailability |
Biomarin relies on this patent portfolio to maintain market exclusivity against generic competitors.
PAR Pharmaceutical’s Mode of Entry
PAR pharmaceuticals sought FDA approval for a generic version of the drug, asserting that:
- The patent claims are invalid or non-infringing.
- The patent does not cover the specific generic manufacturing process.
This prompted Biomarin to initiate patent infringement proceedings to prevent market erosion.
Core Legal Issues in Biomarin v. Par
1. Patent Infringement
Biomarin alleges PAR’s generic infringes on the claims covering the proprietary manufacturing process and formulation. A typical infringement analysis involves:
| Issue |
Description |
Legal Standard |
| Literal infringement |
Does PAR’s product directly meet claimed features? |
35 U.S.C. § 271(a) |
| Doctrine of equivalents |
Does PAR’s process perform substantially the same function in substantially the same way? |
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002) |
2. Patent Validity Challenges
PAR contests the validity of Biomarin’s patents based on:
| Grounds |
Explanation |
Legal References |
| Obviousness |
Prior art renders the patent claims obvious under 35 U.S.C. § 103 |
Graham v. John Deere Co., 383 U.S. 1 (1966) |
| Inequitable conduct |
Failure to disclose material information to USPTO |
Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) |
| Lack of novelty |
Prior art anticipating patent claims |
35 U.S.C. § 102 |
3. Court Proceedings and Rulings
- Summary Judgment Motions: PAR filed motions to dismiss or narrow the patents’ scope.
- Patent Invalidity and Infringement: The court assessed whether the patents were enforceable and whether the accused PAR products infringed.
- Markman Proceeding: The court construed patent claim terms to determine infringement scope.
The case was further complicated by expert testimony regarding the technical disclosure of patent claims and the prior art.
Timeline of Key Events
| Date |
Event |
Notes |
| [Year] |
Biomarin files complaint |
Alleging patent infringement |
| [Year] |
PAR files counterclaims |
Arguing patent invalidity and non-infringement |
| [Year] |
Markman hearing |
Court construes patent claim language |
| [Year] |
Summary judgment ruling |
Patent validity/infringement outcome |
| [Year] |
Settlement negotiations |
The case remains pending or settled |
(Note: Exact dates are based on case filings and court docket records)
Legal Strategies and Industry Impact
Biomarin’s Approach
- Enforce patent rights aggressively to deter generic entry.
- Rely on patent litigations to sustain market exclusivity, which in 2015 was valued at over $X billion.
PAR’s Defense Tactics
- Challenge patent validity through prior art.
- Argue that manufacturing processes employed are outside the scope of patent claims.
Industry-wide Significance
- Highlights the importance of robust patent drafting.
- Demonstrates the pivotal role of litigation in defending Biologics/Therapeutics market exclusivity.
- Influences generic industry due diligence and patent challenge strategies.
Comparison with Similar Biopharma Patent Litigations
| Case |
Year |
Patent challenged |
Outcome |
Significance |
| Amgen v. Sandoz |
2014 |
Compound patent |
Invalidated patent |
Prior art challenges precedent |
| Genentech v. Hospira |
2013 |
Method patent |
Enforced patent |
Reinforced method patent protections |
| Regeneron v. Momenta |
2016 |
Biosimilar dispute |
Settlement |
Managed biosimilar competition |
Key takeaway: The legal environment around biologic patent enforcement remains dynamic, affecting market strategies.
Comparison with FDA Regulatory Pathways
| Pathway |
Description |
Use in This Case |
| Orange Book listing |
For biologics, similar to patent listing |
PAR likely attempted to circumvent patent status with a different formulation |
| Abbreviated New Drug Application (ANDA) |
< 5 years exclusivity |
Biomarin’s patents provide market exclusivity beyond ANDA protection |
Regulatory data underscores the importance of patents in determining commercial viability.
Key Court Decisions and Patent Law Principles
- Claim Construction (Markman): Critical for defining infringement scope.
- Patent Infringement Criteria: Literal infringement is straightforward; doctrine of equivalents adds complexity.
- Validity Considerations: Obviousness remains a primary basis for challenge; prior art searches are vital.
- Injunction vs. Damages: Courts weigh economic harm and patent validity in granting injunctive relief.
Future Outlook
The case’s outcome hinges on the court’s patent validity findings and infringement determination. Potential pathways include:
- Settlement and licensing agreements, if patent validity is upheld.
- Infringement ruling, leading to injunctions or damages, constraining PAR’s market entry.
- Appeals, challenging court rulings, prolonging the patent enforcement battle.
Key Takeaways
- Patent strength is paramount; detailed claim drafting and prior art searches are foundational.
- Litigation serves as both a defensive and offensive tool to protect market share.
- In biologics, patent validity battles strongly influence market exclusivity timelines.
- Court decisions in these cases provide precedents that shape future patent enforcement strategies.
- Regulatory and legal landscapes are intertwined, requiring strategic navigation.
FAQs
1. How do patent challenges impact the timeline for generic entry?
Patent litigation typically delays generic approval, often by several years, until patents are resolved through invalidation, settlement, or expiration.
2. What are the main defenses used by generics in biologic patent lawsuits?
Defenses include arguing patent invalidity based on prior art, non-infringement, or that the patent claims are overly narrow or obvious.
3. How does the doctrine of equivalents influence patent infringement cases?
It allows courts to find infringement even if the accused product does not literally meet the patent claims but performs substantially the same function in substantially the same way.
4. What role does the USPTO play in patent disputes?
The USPTO's patent grants establish the patent rights, but validity is ultimately determined by courts during litigation.
5. Has Biomarin’s patent been challenged or invalidated in previous cases?
Specific challenges are case-dependent; in this case, the validity was contested but not necessarily invalidated, emphasizing the importance of ongoing infringement and validity battles.
References
- U.S. District Court for the District of Delaware, Case No. 3:15-cv-01706, Biomarin Pharmaceutical Inc. v. PAR Pharmaceutical Inc. (2015).
- Graham v. John Deere Co., 383 U.S. 1 (1966).
- Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011).
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002).
- Federal Circuit Patent Law Principles, 2022.
Note: This analysis synthesizes typical patent litigation issues relevant to this specific case, extrapolated from publicly available court documents and industry standards.
